SNAP-CAR T

THE IMPORTANCE
OF CAR T CELL THERAPY 

Chimeric antigen receptor (CAR) therapy is a new treatment for cancer in which a patient's T cells (a type of immune cell) are genetically engineered to recognize cancer cells to target and destroy them. Cells are extracted from the patient and then genetically engineered to make the CAR and are re-introduced back into the patient. Currently approved CAR T therapies are revolutionizing the treatment of many blood cancers including B cell leukemias and lymphomas by targeting specific proteins found on these cancers, and there is hope in treating additional cancers including solid tumors by having them recognize new targets.

WHAT is
SNAP-CAR AND HOW DOES IT TARGET CERTAIN CANCERS?

Coeptis has licensed a CAR T cell therapy platform called "SNAP-CAR" to be a universal therapeutic. The SNAP-CAR technology is in preclinical development at the University of Pittsburgh. Instead of directly binding to a target on the tumor cell, the CAR T cells are co-administered with one or more antibody adaptors that bind to the tumor cells and are fitted with a chemical group that irreversibly connects them to the SNAP-CAR on the therapeutic cells via a covalent bond. A covalent bond is the highest affinity bond possible, thus this binding is expected to translate to highly potent therapeutic activity.

SNAP-CAR,
A HIGHLY PROGRAMMABLE THERAPEUTIC PLATFORM

Pre-clinical studies in mice have demonstrated by targeting tumors via antibody adaptor molecules, the SNAP-CAR therapy provides a highly programmable therapeutic platform that may present several potential advantages over standard CAR T treatments.

 

SNAP-CAR
DEVELOPMENT STRATEtGY

Animations herein are provided as visual aids to help articulate hypothesized proof-of-concept in a general manner and do not depict precise scientific mechanisms-of-action.

IMMUNOTHERAPY CHALLENGES

Reducing potential toxicity: The therapeutic activity of the SNAP-CAR T cells can be controlled by the antibody dose, which we envision would allow clinicians to potentially mitigate toxicity from over-activity. We also envision that the immune response against cancer may also be boosted in patients with additional doses of the tagged tumor-specific antibody. 

THE GOAL

Lowering the chance for cancer relapse: Relapse from CAR T cell therapy which often results from the loss or down-regulation of the targeted protein on the cancer, can potentially be avoided by combining SNAP-CAR T cells with antibodies targeting multiple antigens at once. 

A NOVEL APPROACH

Targeting new cancers: SNAP-CAR T cells are a platform technology that is being developed to be co-administered with tagged, tumor-specific antibodies to potentially target many different tumor types, including hematological malignancies and solid tumors.

Contact Us

Learn More